吉西他滨胸腔灌注治疗NSCLC致恶性胸腔积液的临床疗效

目的观察胸腔灌注吉西他滨治疗NSCLC致恶性胸腔积液的疗效。方法 80例NSCLC伴恶性胸腔积液患者随机分为2组,实验组予胸腔灌注吉西他滨1.0g～1.2g/次,对照组予胸腔灌注顺铂60mg～80mg/次,每周用药1次,连用3周。结果吉西他滨组、顺铂组治疗总有效率分别为85.7%和78.9%,差异无统计学意义。吉西他滨组生活质量改善率优于顺铂组(P<0.05),两组毒副反应相近。结论胸腔灌注吉西他滨治疗NSCLC致恶性胸腔积液有良好疗效,且毒副作用轻,生活质量改善明显。

Clinical Effect of Intrapleural Infusion of Gemcitabine in Malignant Pleural Effusion of NSCLC

Objective To evaluate the clinical efficacy of intrapleural infusion of gemcitabine in treating malignant pleural effusion of NSCLC(non-small-cell lung cancer).Methods 80 patients were divided into two groups in random: experimental group and control group.Gemcitabine was administered to the experimental group intrathoracically in a dose of 1.0-1.2g once a week for 3 consecutive weeks,while cisplatin to the control group in a dose of 60-80mg.Results fAfter treatment,the total effective rate was 85.7% in gemcitabine group and 78.9% in cisplatin group.There was no statistical difference between them.The gemcitabine group had a better quality of life improvement than the cisplatin group(P<0.05).Side effects were similar in both groups.Conclusions Intrapleural infusion of gemcitabine is effective for malignant pleural effusion of NSCLC with mild side effects and could remarkably improve the quality of life for patients.